Abiopharma

New Form 8-K - ProPhase Labs, Inc. Filed: 2025-08-19 AccNo: 0001641172-25-024730 Size: 257 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Masimo - Masimo O3® Regional Oximetry Receives FDA Clearance for Expanded Indication of Its Unique Delta Hemoglobin Parameters

ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders

Ensysce Biosciences Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

New Form 10-K - Premier, Inc. Filed: 2025-08-19 AccNo: 0001577916-25-000011 Size: 14 MB

New Form 8-K - OptimizeRx Corp Filed: 2025-08-19 AccNo: 0001213900-25-078162 Size: 260 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Aveanna to Participate at the Deutsche Bank Healthcare Summit

Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer

OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Agenus Inc. - Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

KIRK THOMAS F acquired 50.0k shares of MYOMO, INC. (MYO) at average price $1.10 Filed: 2025-08-19 AccNo: 0000950170-25-109938 Size: 4 KB

New Form 8-K - Viking Therapeutics, Inc. Filed: 2025-08-19 AccNo: 0001607678-25-000003 Size: 325 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity